Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Ractigen Therapeutics announced that LiCO-saUcp1, its first-in-class saRNA obesity therapy, was accepted for a late-breaking poster at ADA 2026 in New Orleans. The ADA 2026 sessions run June 5-8, and the firm states LiCO-saUcp1 activates Ucp1-driven thermogenesis to drive fat loss while preserving lean muscle. In diet-induced obesity models, LiCO-saUcp1 reduced fat mass by 45 percent without losing lean mass, versus 19 percent with semaglutide. Withdrawal maintained a 46 percent fat-mass reduction for two months, compared with rebound after semaglutide.

When combined with semaglutide, LiCO-saUcp1 reduced fat by 69 percent vs 47 percent for semaglutide alone. The therapy also cut liver triglycerides by up to 79 percent, signaling liver health benefits. Ractigen argues saRNA activation safely unlocks Ucp1 thermogenesis, offering a differentiated obesity approach. CEO Long-Cheng Li calls the data a new frontier in obesity care, pending further validation in development.